Fuzhou Medical College of Nanchang University, Fuzhou, China.
Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
BMJ Open. 2024 Mar 8;14(3):e084520. doi: 10.1136/bmjopen-2024-084520.
Lung cancer remains the largest cause of cancer-related deaths worldwide. Surgical removal of non-small cell lung cancer (NSCLC) has the potential to achieve a cure, although there is ongoing debate regarding the significance of removing mediastinal nodes and the optimal extent of lymph node excision. The purpose of this research is to assess the survival outcomes in patients diagnosed with stage I-IIIA NSCLC who received either complete mediastinal lymphadenectomy (CML) or selective mediastinal lymphadenectomy (SML).
The protocol follows the guidelines recommended in Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, and this meta-analysis will be conducted in accordance with the standard methodology recommended by the Cochrane Collaboration and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidance. We will conduct a comprehensive search for randomised controlled trials and non-randomised studies examining the effectiveness of CML compared with SML in patients with stage I-IIIA NSCLC. Two authors will perform a comprehensive search of the MEDLINE/PubMed, Embase, the Cochrane Library, CNKI, WanFang, Sinomed, VIP and Web of Science databases. There will be no restrictions on language or publication date, and the search will be conducted on 10 April 2024, with ongoing searches for new research. Reference lists will also be checked and pertinent journals will be hand searched. The primary outcomes include overall survival (OS) and disease-free survival (DFS), while the secondary outcomes consist of 1-year, 3-year and 5-year OS rates and 1-year, 3-year and 5-year DFS rates. Two independent reviewers will screen, extract data, assess quality and evaluate the potential for bias in the selected research, with a third acting as arbitrator. Subgroup analyses and sensitivity analyses are planned. The quality of the evidence will be evaluated using Grading of Recommendations Assessment, Development and Evaluation. Review Manager V.5.4 will be used for the analysis and synthesis process.
Ethical review and approval are not necessary for this study because it is based on a secondary analysis of the literature. The results will be submitted for reporting in a peer-reviewed publication.
Open Science Framework (https://doi.org/10.17605/OSF.IO/PN7UQ).
肺癌仍然是全球癌症相关死亡的最大原因。手术切除非小细胞肺癌 (NSCLC) 有治愈的潜力,尽管关于切除纵隔淋巴结的意义和淋巴结切除的最佳范围仍存在争议。本研究旨在评估接受完全纵隔淋巴结清扫术 (CML) 或选择性纵隔淋巴结清扫术 (SML) 的 I 期-IIIA 期 NSCLC 患者的生存结果。
该方案遵循系统评价和荟萃分析推荐的首选报告项目指南,并且该荟萃分析将按照 Cochrane 协作组推荐的标准方法进行,并按照 2020 年系统评价和荟萃分析首选报告项目指南进行报告。我们将全面检索比较 I 期-IIIA 期 NSCLC 患者 CML 与 SML 有效性的随机对照试验和非随机研究。两名作者将全面检索 MEDLINE/PubMed、Embase、Cochrane 图书馆、CNKI、万方、中国生物医学文献服务系统、维普和 Web of Science 数据库。语言和出版日期没有限制,检索时间为 2024 年 4 月 10 日,并且会持续搜索新的研究。还将检查参考文献列表并手动搜索相关期刊。主要结局包括总生存 (OS) 和无病生存 (DFS),次要结局包括 1 年、3 年和 5 年 OS 率和 1 年、3 年和 5 年 DFS 率。两名独立评审员将筛选、提取数据、评估质量和评估所选研究的偏倚可能性,第三名作为仲裁员。计划进行亚组分析和敏感性分析。使用推荐评估、制定和评价分级法评估证据质量。Review Manager V.5.4 将用于分析和综合过程。
本研究不需要伦理审查和批准,因为它是基于文献的二次分析。研究结果将提交同行评审出版物报告。
Open Science Framework (https://doi.org/10.17605/OSF.IO/PN7UQ)。